Literature DB >> 22783917

The cost of providing methadone maintenance treatment in Ontario, Canada.

Gregory S Zaric1, Andrew W Brennan, Michael Varenbut, Jeff M Daiter.   

Abstract

OBJECTIVES: To estimate the cost of providing methadone maintenance treatment in Ontario, Canada, from the perspective of the public payer.
METHODS: We analyzed a database of all patient clinic visits, laboratory tests for urine toxicology screening, and methadone scripts from a group of methadone clinics in Ontario. The database consisted of patient visits and visit information from 1 January 2003 to 31 December 2009. We estimated the cost of providing methadone maintenance treatment as the sum of physician costs, laboratory costs for urine samples (toxicology screens), methadone costs, and pharmacy costs. Pharmacy costs include dispensing fees and markups. All costs are expressed in 2010 Canadian dollars.
RESULTS: The database consisted of 9479 unique patients. The average age on the date of the first recorded visit was 34.3, and among the patients 62.3% were male. There were 6,425,937 patient days of treatment and the total cost of all treatment-related services was approximately $99,491,000. The total cost was comprised of physician billing (9.8%), pharmacy costs (39.8%), methadone (3.8%), and performing urine toxicology screens (46.7%). The average cost per day for treatment was $15.48, corresponding to $5651per year if patients were to remain in treatment continuously.
CONCLUSIONS: The cost of providing methadone maintenance treatment in Ontario is comparable to estimates from the United States and Australia. SCIENTIFIC SIGNIFICANCE: This information is important to policy makers for planning and budgeting purposes and as part of a full cost-benefit or cost-effectiveness analysis of methadone treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22783917      PMCID: PMC3626407          DOI: 10.3109/00952990.2012.694518

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  22 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  The economic costs of substance abuse treatment: updated estimates and cost bands for program assessment and reimbursement.

Authors:  Michael T French; Ioana Popovici; Lauren Tapsell
Journal:  J Subst Abuse Treat       Date:  2008-02-21

3.  The costs and consequences of three policy options for reducing heroin dependency.

Authors:  Timothy J Moore; Alison Ritter; Jonathan P Caulkins
Journal:  Drug Alcohol Rev       Date:  2007-07

4.  Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.

Authors:  Emlyn S Jones; Brent A Moore; Jody L Sindelar; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2008-09-19       Impact factor: 4.492

5.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

Review 6.  The cost-effectiveness of methadone maintenance as a health care intervention.

Authors:  P G Barnett
Journal:  Addiction       Date:  1999-04       Impact factor: 6.526

Review 7.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

8.  The cost of treating addiction from the client's perspective: results from a multi-modality application of the Client DATCAP.

Authors:  Kathryn E McCollister; Michael T French; Jeffrey M Pyne; Brenda Booth; Richard Rapp; Carey Carr
Journal:  Drug Alcohol Depend       Date:  2009-07-01       Impact factor: 4.492

9.  The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; Suzanne Brissette; Jill Chettiar; Pascal Schneeberger; David C Marsh; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  J Urban Health       Date:  2008-08-29       Impact factor: 3.671

10.  Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.

Authors:  Eugenia Oviedo-Joekes; Bohdan Nosyk; David C Marsh; Daphne Guh; Suzanne Brissette; Candice Gartry; Michael Krausz; Aslam Anis; Martin T Schechter
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more
  7 in total

1.  Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?

Authors:  Paul Kurdyak; Binu Jacob; Juveria Zaheer; Benedikt Fischer
Journal:  Can Fam Physician       Date:  2018-02       Impact factor: 3.275

2.  Quality of primary care among individuals receiving treatment for opioid use disorder.

Authors:  Sheryl Spithoff; Tara Kiran; Wayne Khuu; Meldon Kahan; Qi Guan; Mina Tadrous; Pamela Leece; Diana Martins; Tara Gomes
Journal:  Can Fam Physician       Date:  2019-05       Impact factor: 3.275

3.  Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.

Authors:  Jose Luis Burgos; Javier A Cepeda; James G Kahn; Maria Luisa Mittal; Emilio Meza; Raúl Rafael Palacios Lazos; Psyché Calderón Vargas; Peter Vickerman; Steffanie A Strathdee; Natasha K Martin
Journal:  Harm Reduct J       Date:  2018-05-23

4.  Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada.

Authors:  Kristen A Morin; Joseph K Eibl; Joseph M Caswell; Graham Gauthier; Brian Rush; Christopher Mushquash; Nancy E Lightfoot; David C Marsh
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-06-26

5.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

6.  Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'?

Authors:  Benedikt Fischer; Paul Kurdyak; Elliot Goldner; Mark Tyndall; Jürgen Rehm
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-03-08

7.  Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.

Authors:  Adrian J Dunlop; Bethany White; Jillian Roberts; Michelle Cretikos; Dena Attalla; Rod Ling; Andrew Searles; Judith Mackson; Michael F Doyle; Elizabeth McEntyre; John Attia; Christopher Oldmeadow; Mark V Howard; Terry Murrell; Paul Steven Haber; Nicholas Lintzeris
Journal:  Addiction       Date:  2021-07-16       Impact factor: 7.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.